Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Electrocardiographic Effects of Ponesimod in Healthy Subjects
NCT02136888Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2011
- Primary completion
- Feb 2012
- Modality
- Covalent Small Molecules, Molecular Glues, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing Ponesimod with Placebo / Moxifloxacin (2 arms). Primary endpoint: Baseline-adjusted, placebo-corrected effect on QTc interval at Day 23. Started Aug 2011; status: completed.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02136888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02136888.